Supporting Women’s Health Choices—Challenges Facing Breast Cancer Survivors Today
Menée en France sur la période 2012-2017 auprès de 2 900 patientes atteintes d'un cancer du sein de stade I-III (âge moyen : 43,1 ans), cette étude multicentrique analyse les facteurs associés au choix de la contraception utilisée au moment du diagnostic, peu après la fin du traitement anticancéreux et pendant le suivi
Limited evidence exists on the use of contraceptive methods among breast cancer survivors. Lambertini and colleagues report on the use of contraception among premenopausal women with early-stage breast cancer who participated in the multicenter Cancer Toxicity (CANTO) cohort study, finding that at the time of diagnosis, 54.2% of patients reported contraceptive use, with most women choosing hormonal methods. After diagnosis and during follow-up, the use of contraception decreased significantly to approximately 40% (38.9% at year 1 and 41.2% at year 2), and most patients reported using reversible mechanical methods.